5:00 PM - 5:15 PM, Monday, June 3,2019 ・ Theater 1
ISOThrive is a microbiome inspired therapeutics company that has developed a novel patented and patents-pending treatment targeting gastroesophageal reflux disease (a.k.a. GERD or chronic acid reflux). Our unique carbohydrate is designed to restore the normal localized microbiome at the lower esophageal sphincter, and thereby stop acid reflux at the root cause. In addition, there is growing evidence that suggests that the abnormal microbiome that exists with GERD, and the chronic inflammation that results, may be the cause of the progression of GERD to Barrett’s Esophagus and ultimately to cancer of the esophagus. By restoring the normal local microbiome, ISOThrive may also prevent esophageal cancer. ISOThrive’s microbiome inspired platform addresses many other indications including IBS and colorectal cancer.
co-founder, CEO and CTO